PODCAST · business
Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals
by Fexingo
Lucas and Luna step into the clean, cool world of biotechnology startups, where drug discovery meets the harsh realities of FDA approvals and venture capital. Each episode takes a single biotech company—from Moderna to a tiny CRISPR spinout—and dissects its science, its business model, and the regulatory path that determines its fate. Lucas brings the numbers: clinical trial phases, patent cliffs, burn rates. Luna presses on the human stories: the researchers betting careers on a single molecule, the patients waiting for therapies that might never come. They don't celebrate hype; they ask whether the science holds up, whether the market exists, and whether the FDA will say yes. Listeners will walk away able to read a biotech 10-K, understand a Phase II readout, and spot the difference between a genuine breakthrough and a stock promotion. How do you value a company with no revenue and a 90% chance of failure?
No episodes available yet.
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Lucas and Luna step into the clean, cool world of biotechnology startups, where drug discovery meets the harsh realities of FDA approvals and venture capital. Each episode takes a single biotech company—from Moderna to a tiny CRISPR spinout—and dissects its science, its business model, and the regulatory path that determines its fate. Lucas brings the numbers: clinical trial phases, patent cliffs, burn rates. Luna presses on the human stories: the researchers betting careers on a single molecule, the patients waiting for therapies that might never come. They don't celebrate hype; they ask whether the science holds up, whether the market exists, and whether the FDA will say yes. Listeners will walk away able to read a biotech 10-K, understand a Phase II readout, and spot the difference between a genuine breakthrough and a stock promotion. How do you value a company with no revenue and a 90% chance of failure?
HOSTED BY
Fexingo
CATEGORIES
Loading similar podcasts...
URL copied to clipboard!